+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Migraine - Global Drug Forecast and Market Analysis to 2030

  • ID: 5505243
  • Report
  • November 2021
  • Region: Global
  • 131 Pages
  • GlobalData
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • AbbVie
  • Biohaven Pharmaceuticals
  • Eli Lilly
  • GlaxoSmithKline
  • Merck
  • Pfizer
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Migraine is a complex neurological condition characterized by frequent headaches that can last between four and 72 hours. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.
The two clinically and commercially relevant segments considered for the classification of migraine in this report are patients with episodic migraine, who suffer up to 14 migraines per month, and patients with chronic migraine, who suffer 15 or more attacks per month.

For patients that experience four or more migraine attacks per month, physicians look to prescribe a preventive treatment. Preventive treatment is considered an additive to acute therapy and minimizes the risk of medication overuse headaches associated with Nonsteroidal anti-inflammatory drug (NSAID) and triptan treatment.

The migraine market in the 7MM was valued at $4.7B in the 2020 baseline year. The publisher anticipates that over the 10-year forecast period, the market is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.9%, reaching $12.0B by 2030. The major driver for this growth will be the increased prescription of calcitonin gene-related peptide (CGRP) antagonists, gepants, and monoclonal antibodies (mAbs). In addition, the launch of five new pipeline products which will have higher annual costs of therapy (ACOTs) when compared with the cost of the most commonly used migraine treatments, will drive further growth into this market. In order of entry, these products will include Axsome Therapeutics’ AXS-07, Zosano Pharma’s Qtrypta, Biohaven Pharmaceutical’s zavegepant (intranasal), Satsuma Pharmaceuticals’ STS101, and Biohaven Pharmaceutical’s zavegepant (oral).

Key Highlights

  • The prevalence of migraine is increasing in line with population growth in the 7MM.
  • Oral triptans are the first-line therapy for acute migraine treatment. First-line therapies for migraine prophylaxis depend on the patients’ comorbidities and include anti-epileptic agents, antidepressants, beta blockers, and angiotensin receptor blockers.
  • The greatest unmet need in the migraine market is access to effective and tolerable prophylactic treatments, in addition to the need for more efficacious acute therapy options.
  • The migraine pipeline is dominated by reformulations of mature products with novel delivery devices that provide preferable route of administration to patients.
  • The migraine market will exhibit significant growth between 2020 and 2030, driven by the increased prescription of anti-CGRP mAbs and small molecule CGRP antagonists, gepants.

Key Questions Answered

  • What are the key migraine treatments available in 2020?
  • When will the late stage pipeline products launch, and how will it affect drug sales and the overall migraine market in the 7MM?
  • Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope

  • Overview of migraine, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic migraine and chronic migraine) forecast from 2020 to 2030.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the migraine therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine treatment. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global migraine therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global migraine therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie
  • Biohaven Pharmaceuticals
  • Eli Lilly
  • GlaxoSmithKline
  • Merck
  • Pfizer

1 Migraine: Executive Summary
1.1 Migraine Therapeutics Market will grow to $12.0B
1.2 Key Players Will Maintain Their Competitive Position
1.3 Access to Effective and Tolerable Prophylactic Treatments and Additional Acute Therapy Options Remain Unmet Needs
1.4 The Gepants Are the Most Promising New Entrants to the Migraine Market
1.5 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or Staging Systems
3.2.1 Premonitory Phase
3.2.2 Aura Phase
3.2.3 Headache Phase
3.2.4 Resolution Phase
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 7MM Forecast Methodology
4.4.1 Sources Used
4.4.2 Forecast Assumptions and Methods
4.4.3 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine
4.4.4 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine by Frequency
4.4.5 12-Month Total Prevalent Cases of Migraine by Type
4.4.6 12-Month Diagnosed Prevalent Cases of Migraine
4.5 Epidemiological Forecast for Migraine (2020-2030)
4.5.1 12-Month Total Prevalent Cases of Migraine
4.5.2 Age-Specific 12-Month Total Prevalent Cases of Migraine
4.5.3 Sex-Specific 12-Month Total Prevalent Cases of Migraine
4.5.4 12-Month Total Prevalent Cases of Migraine by Frequency of Episodic and Chronic
4.5.5 12-Month Total Prevalent Cases of Migraine by Type
4.5.6 12-Month Diagnosed Prevalent Cases of Migraine
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of the Analysis
4.6.4 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.1.1 Episodic Migraine
5.1.2 Chronic Migraine
5.2 Additional KOL Insights on Disease Management
6 Competitive Assessment
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Acute Therapies for Patients with, or at Risk of, Cardiovascular Disorders
7.3 Limited Acute Therapies for Patients Unresponsive to Triptan Medication
7.4 Access to Effective and Tolerable Prophylactic Treatments
7.5 Physician Education for Diagnosis
7.6 Raise Awareness of the Disease in the General Population
8 R&D Strategies
8.1 Overview
8.1.1 Gepants for Dual-Acting Acute and Preventive Indications
8.1.2 Preventive Drugs with Long Duration of Action
8.1.3 Improving Efficacy of Marketed Migraine Drugs
8.1.4 Novel MOAs
8.2 Clinical Trials Design
8.2.1 Study Design
8.2.2 Endpoints for Migraine Clinical Trials
8.2.3 Patient Recruitment
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
10.2.1 Acute Treatment for Migraine
10.2.2 Preventive Treatment for Migraine
11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers - Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and Barriers
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting Methodology
13.4 Primary Research - KOLs Interviewed for This Report
13.4.1 KOLs
13.5 Primary Research - Prescriber Survey
13.6 About the Authors
13.6.1 Analyst
13.6.2 Managing Analyst
13.6.3 Therapy Area Director
13.6.4 Epidemiologist
13.6.5 Managing Epidemiologist
13.6.6 Global Director of Therapy Analysis and Epidemiology
13.6.7 Global Head and EVP of Healthcare Operations and Strategy
Contact The Publisher
List of Tables
Table 1: Disease Migraine: Key Metrics in the 7MM
Table 2: Migraine Classification from the ICHD-3
Table 3: Diagnostic Criteria for Migraine with Aura
Table 4: Diagnostic Criteria for Migraine without Aura
Table 5: Risk Factors and Comorbidities for Migraine
Table 6: Treatment Guidelines for Disease Migraine
Table 7: Most Prescribed Drugs for Migraine by Class in the 7MM
Table 8: Migraine Market - Global Drivers and Barriers, 2020-2030
Table 9: Key Events Impacting Sales for Migraine in the US, 2020-2030
Table 10: Migraine Market - Drivers and Barriers in the US, 2020-2030
Table 11: Key Events Impacting Sales for Migraine in the 5EU, 2020-2030
Table 12: Migraine Market - Drivers and Barriers in the 5EU, 2020-2030
Table 13: Key Events Impacting Sales for Migraine in Japan, 2020-2030
Table 14: Migraine Market - Drivers and Barriers in Japan, 2020- 2030
Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for Migraine in 2020 and 2030
Figure 2: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period
Figure 3: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for Acute Migraine Treatment, Imitrex.
Figure 4: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC for Preventive Migraine Treatment, generic propranolol.
Figure 5: Pathophysiology of a Migraine
Figure 6: 7MM, 12-Month Total Prevalence of Migraine, Men and Women, %, Ages =18 Years, 2020
Figure 7: 7MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of Migraine
Figure 8: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Frequency
Figure 9: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Type
Figure 10: 7MM, Sources Used to Forecast the Diagnosis Rate of Migraine
Figure 11: 7MM, 12-Month Total Prevalent Cases of Migraine, N, Both Sexes, Ages =18 Years, 2020
Figure 12: 7MM, 12-Month Total Prevalent Cases of Migraine by Age, N, Both Sexes, 2020
Figure 13: 7MM, 12-Month Total Prevalent Cases of Migraine by Sex, N, Ages =18 Years, 2020
Figure 14: 7MM, 12-Month Total Prevalent Cases of Migraine by Frequency, N, Both Sexes, Ages =18 Years, 2020
Figure 15: 7MM, 12-Month Total Prevalent Cases of Migraine by Type, N, Both Sexes, Ages =18 Years, 2020
Figure 16: 7MM, 12-Month Diagnosed Prevalent Cases of Migraine, N, Both Sexes, Ages =18 Years, 2020
Figure 17: Unmet Needs and Opportunities in Migraine
Figure 18: Overview of the Development Pipeline in Migraine
Figure 19: Key Late-Stage Trials for the Promising Pipeline Agents that The Publisher Expects to Be Licensed for Migraine in the 7MM During the Forecast Period
Figure 20: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for Acute Migraine Treatment, Imitrex.
Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC for Preventive Migraine Treatment, generic propranolol.
Figure 22: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period
Figure 23: Global (7MM) Sales Forecast by Country for Migraine in 2020 and 2030
Figure 24: Global (7MM) Sales Forecast by Drug Class for Migraine in 2020 and 2030
Figure 25: Sales Forecast by Class for Migraine in the US in 2020 and 2030
Figure 26: Sales Forecast by Class for Migraine in the 5EU in 2020 and 2030
Figure 27: Sales Forecast by Class for Migraine in the Japan in 2020 and 2030
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AbbVie
  • Amgen
  • Axsome Therapeutics
  • Biohaven Pharmaceuticals
  • Bristol-Myers Squibb
  • Currax Pharmaceuticals
  • Eli Lilly
  • Endo International
  • Exeltis Healthcare
  • GlaxoSmithKline
  • H.Lundbeck
  • Impel NeuroPharma
  • Merck
  • Novartis
  • Old API Wind-down
  • Pfizer
  • Teva Pharmaceuticals
  • Satsuma Pharmaceuticals
  • Sosei Heptares
  • Zosano Pharma Corp
Note: Product cover images may vary from those shown